Literature DB >> 18508225

The burden of vancomycin-resistant enterococcal infections in US hospitals, 2003 to 2004.

Rebecca Reik1, Fred C Tenover, Eili Klein, L Clifford McDonald.   

Abstract

Despite significant concern in the health care community regarding vancomycin-resistant enterococci (VRE), there are no estimates of the total number of VRE infections that occur each year in US hospitals. Using data from a national survey of hospital discharges and a national antimicrobial resistance surveillance system, we estimated the annual number of US hospitalization with VRE bloodstream, urinary tract, and wound or intra-abdominal infections. Because of the inexact nature of hospital discharge diagnosis coding, we made both a conservative and liberal estimate of hospitalization with VRE infection by using a variety of data sources. For the years 2003 and 2004, we conservatively estimated that there were 20777 and 20931 VRE infections, respectively; for those same years, the liberal estimates were 78330 and 85586, respectively. Because there are such a large number of hospital discharges for which an infection is coded without an organism code, it is likely that the conservative estimate is an underestimate of the true burden. These estimates highlight the importance of controlling VRE and the need to develop improved methods for tracking the burden of such infections.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18508225     DOI: 10.1016/j.diagmicrobio.2008.04.013

Source DB:  PubMed          Journal:  Diagn Microbiol Infect Dis        ISSN: 0732-8893            Impact factor:   2.803


  20 in total

1.  Association between vancomycin-resistant Enterococci bacteremia and ceftriaxone usage.

Authors:  James A McKinnell; Danielle F Kunz; Eric Chamot; Mukesh Patel; Rhett M Shirley; Stephen A Moser; John W Baddley; Peter G Pappas; Loren G Miller
Journal:  Infect Control Hosp Epidemiol       Date:  2012-05-14       Impact factor: 3.254

2.  Effect of Continuous and Sequential Therapy among Veterans Receiving Daptomycin or Linezolid for Vancomycin-Resistant Enterococcus faecium Bacteremia.

Authors:  Nicholas S Britt; Emily M Potter; Nimish Patel; Molly E Steed
Journal:  Antimicrob Agents Chemother       Date:  2017-04-24       Impact factor: 5.191

3.  Isolation and characterization of a novel bacteriophage φ4D lytic against Enterococcus faecalis strains.

Authors:  Sylwia Parasion; Magdalena Kwiatek; Lidia Mizak; Romuald Gryko; Michał Bartoszcze; Janusz Kocik
Journal:  Curr Microbiol       Date:  2012-06-06       Impact factor: 2.188

4.  Observational study of the epidemiology and outcomes of vancomycin-resistant Enterococcus bacteraemia treated with newer antimicrobial agents.

Authors:  J A McKinnell; M Patel; R M Shirley; D F Kunz; S A Moser; J W Baddley
Journal:  Epidemiol Infect       Date:  2010-11-15       Impact factor: 2.451

5.  Vancomycin resistance has no influence on outcomes of enterococcal bacteriuria.

Authors:  H N Khair; P VanTassell; J P Henderson; D K Warren; J Marschall
Journal:  J Hosp Infect       Date:  2013-08-30       Impact factor: 3.926

6.  Comparison of the Effectiveness and Safety of Linezolid and Daptomycin in Vancomycin-Resistant Enterococcal Bloodstream Infection: A National Cohort Study of Veterans Affairs Patients.

Authors:  Nicholas S Britt; Emily M Potter; Nimish Patel; Molly E Steed
Journal:  Clin Infect Dis       Date:  2015-06-10       Impact factor: 9.079

7.  Role of house flies in the ecology of Enterococcus faecalis from wastewater treatment facilities.

Authors:  C W Doud; H M Scott; L Zurek
Journal:  Microb Ecol       Date:  2013-12-14       Impact factor: 4.552

8.  The changing epidemiology of vancomycin-resistant Enterococcus (VRE) bacteremia in allogeneic hematopoietic stem cell transplant (HSCT) recipients.

Authors:  Mini Kamboj; Dick Chung; Susan K Seo; Eric G Pamer; Kent A Sepkowitz; Ann A Jakubowski; Genovefa Papanicolaou
Journal:  Biol Blood Marrow Transplant       Date:  2010-05-26       Impact factor: 5.742

9.  Epidemiology of vancomycin-resistant enterococci in Canadian hospitals (CANWARD study, 2007 to 2013).

Authors:  P J Simner; H Adam; M Baxter; M McCracken; G Golding; J A Karlowsky; K Nichol; P Lagacé-Wiens; M W Gilmour; D J Hoban; G G Zhanel
Journal:  Antimicrob Agents Chemother       Date:  2015-04-20       Impact factor: 5.191

10.  Outcomes of Aminopenicillin Therapy for Vancomycin-Resistant Enterococcal Urinary Tract Infections.

Authors:  Kelli A Cole; Rachel M Kenney; Mary Beth Perri; Lisa E Dumkow; Linoj P Samuel; Marcus J Zervos; Susan L Davis
Journal:  Antimicrob Agents Chemother       Date:  2015-09-14       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.